insights_auto
Outlook: 74.1% bullish·0.0% bearish
Go to analysischevron_right
REGN:NASDAQ
Regeneron Pharmaceuticals Inc
US$ ७५३.१२
arrow_downward
-१.२७%(-९.६९) 1D
US$ ७५३.१२
०.००% (०.००)
bedtimeAfter hours
Closed: अक्टोबर १३, १६:००:०० GMT-४ · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for REGN...
Open
US$ ७६२.४८
High
US$ ७६५.६०
Low
US$ ७४३.५७
Mkt. cap
७७.५४ अरब
Avg. vol.
७.१५ लाख
Volume
६.३० लाख
Dividend
०.५०%
Quarterly dividend
US$ ०.९४
Ex-dividend date
२०२६ अगस्ट १८
P/E ratio
१८.६२
52-wk high
US$ ८५९.३४
52-wk low
US$ ५५३.८६
EPS
US$ ४०.४५
Beta
०.१६
Shares outstanding
१०.११ करोड
No. of employees
१५ हजार
Open
US$ ७६२.४८
High
US$ ७६५.६०
Low
US$ ७४३.५७
Mkt. cap
७७.५४ अरब
Avg. vol.
७.१५ लाख
Volume
६.३० लाख
Dividend
०.५०%
Quarterly dividend
US$ ०.९४
Ex-dividend date
२०२६ अगस्ट १८
P/E ratio
१८.६२
52-wk high
US$ ८५९.३४
52-wk low
US$ ५५३.८६
EPS
US$ ४०.४५
Beta
०.१६
Shares outstanding
१०.११ करोड
No. of employees
१५ हजार
News stories
From web sources and news partners
News Corp
·
३ घण्टा पहिले
Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors
ad-hoc-news.de
·
१० घण्टा पहिले
RBC raises target for Regeneron stock to USD 810.00
Zacks
·
११ घण्टा पहिले
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
The Globe and Mail
·
१३ घण्टा पहिले
Citi Keeps Their Hold Rating on Regeneron (REGN)
Profile
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its present name; the company has since expanded operations into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap. Wikipedia
About Regeneron Pharmaceuticals Inc
CEOLeonard Schleifer
Employees१५.३ हजार
Founded१९८८
HeadquartersTarrytown, न्यू योर्क, संयुक्त राज्य अमेरिका
Sector-
Websiteregeneron.com